Nuclear Imaging Finds Insulinomas Missed by Standard Scans in 72% of Cases
A GLP-1 receptor-targeted PET/CT scan located insulin-secreting tumors in nearly three-quarters of patients where conventional imaging had failed.
Summary
Insulinomas — small tumors that cause dangerous low blood sugar — are notoriously difficult to find with standard imaging. A new study tested a specialized nuclear medicine scan called 68Ga-DOTA-exendin-4 PET/CT, which targets GLP-1 receptors overexpressed on these tumors. In 58 patients whose conventional scans were negative or inconclusive, this PET/CT detected the tumor in 72% of cases and achieved a sensitivity of 93.8% when verified by surgery. Thirty patients went on to have guided surgery based on PET/CT results. The findings suggest this advanced imaging tool should become a standard step when conventional imaging fails, potentially sparing patients from exploratory surgery or ongoing uncontrolled hypoglycemia.
Detailed Summary
Insulinomas are rare but serious pancreatic tumors that cause the body to overproduce insulin, leading to recurrent dangerous hypoglycemia. Surgery is the only cure, but pancreas-sparing procedures require knowing exactly where the tumor is located — something conventional imaging often fails to determine. This study evaluated whether a specialized nuclear imaging technique could fill that gap.
Researchers at two European tertiary centers conducted a retrospective analysis of 101 patients with biochemically confirmed endogenous hyperinsulinemic hypoglycemia (EHH). The primary focus was a subset of 58 patients whose prior CT, MRI, or ultrasound had returned negative or inconclusive results. All underwent 68Ga-DOTA-exendin-4 PET/CT, a scan that targets GLP-1 receptors highly expressed on insulinoma cells.
The results were striking. Among patients where conventional imaging had failed, the GLP-1R-targeted PET/CT detected a lesion in 72% of cases (42 of 58). Of the 32 patients with histological confirmation, sensitivity reached 93.8% — meaning the scan correctly identified nearly all true insulinomas. Thirty patients proceeded to PET/CT-guided surgery, with the scan directly influencing surgical planning.
The clinical implications are significant. For a condition where undetected tumors leave patients vulnerable to life-threatening hypoglycemic episodes, a 72% detection rate in previously inconclusive cases represents a major advance. The scan also identified one case of diffuse nesidioblastosis, a rare condition mimicking insulinoma that requires different management.
Caveats include the retrospective, real-world design, which limits causal inference. The study was conducted at specialized centers with expertise in this technique, so results may not generalize to all settings. The full paper was not available for review; this summary is based on the abstract only, and details on patient demographics, imaging protocols, and surgical outcomes remain unknown.
Key Findings
- 68Ga-DOTA-exendin-4 PET/CT detected insulinomas in 72% of patients where conventional imaging failed.
- Sensitivity reached 93.8% among the 32 patients with surgical or histological verification.
- 30 patients underwent PET/CT-guided surgery directly informed by these scan results.
- One case of diffuse nesidioblastosis was identified, illustrating the scan's diagnostic breadth.
- Findings support GLP-1R-targeted PET/CT as a frontline rescue tool when standard imaging is inconclusive.
Methodology
Retrospective dual-center cohort study of 101 patients with biochemically proven EHH seen between 2017–2024; primary analysis focused on 58 patients with prior negative or inconclusive conventional imaging. Endpoints included detection rate and sensitivity confirmed by histopathology where available.
Study Limitations
Retrospective design at two high-volume specialized centers limits generalizability to community settings. Not all patients had histological confirmation, which may affect sensitivity estimates. This summary is based on the abstract only, as the full paper was not accessible; detailed methodology, patient characteristics, and adverse events are unknown.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.